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Background: After completion of embryogenesis, many organisms experience an additional obligatory
developmental transition to attain a substantially different juvenile or adult form. During anuran metamorphosis,
the aquatic tadpole undergoes drastic morphological changes and remodelling of tissues and organs to become a
froglet. Thyroid hormones are required to initiate the process, but the mechanism whereby the many requisite
changes are coordinated between organs and tissues is poorly understood. Metabolites are often highly conserved
biomolecules between species and are the closest reflection of phenotype. Due to the extensive distribution of
blood throughout the organism, examination of the metabolites contained therein provides a system-wide
overview of the coordinated changes experienced during metamorphosis. We performed an untargeted
metabolomic analysis on serum samples from naturally-metamorphosing Rana catesbeiana from tadpoles to froglets
using ultraperformance liquid chromatography coupled to a mass spectrometer. Total and aqueous metabolite
extracts were obtained from each serum sample to select for nonpolar and polar metabolites, respectively, and
selected metabolites were validated by running authentic compounds.
Results: The majority of the detected metabolites (74%) showed statistically significant abundance changes
(padj < 0.001) between metamorphic stages. We observed extensive remodelling of five core metabolic pathways:
arginine and purine/pyrimidine, cysteine/methionine, sphingolipid, and eicosanoid metabolism and the urea cycle,
and found evidence for a major role for lipids during this postembryonic process. Metabolites traditionally linked to
human disease states were found to have biological linkages to the system-wide changes occuring during the
events leading up to overt morphological change.
Conclusions: To our knowledge, this is the first wide-scale metabolomic study of vertebrate metamorphosis
identifying fundamental pathways involved in the coordination of this important developmental process and paves
the way for metabolomic studies on other metamorphic systems including fish and insects.
Keywords: Postembryonic development, Thyroid hormone, Metamorphosis, Metabolites, Serum, Ultra-performance
liquid chromatography, Quadrupole time-of-flight, Mass spectrometry, VertebrateBackground
After embryogenesis, many organisms experience ob-
ligatory developmental transitions to successfully move
from one ecological niche to another. One such transi-
tion is through metamorphosis in which an immature
larva transforms into a juvenile or adult scarcely resem-
bling the initial form. Classic examples occur in verte-
brates and invertebrates alike, and often require the
involvement of hormone signaling systems. However, a* Correspondence: chelbing@uvic.ca
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stated.fundamental question in biology remains in understanding
how a fully-differentiated organism coordinates the many
tissue- and organ-system changes during the metamorphic
process [1,2].
Frog tadpoles undergo significant morphological changes,
resulting in the development of limbs, resorption of the tail,
and a shift from gill to lungs in respiratory organs used,
hence a shift from purely aquatic to a semi-terrestrial life-
style and a change in diet. This extensive process involves
apoptosis, cell proliferation, and reprogramming and high-
lights the complexity, tight regulation, and interconnection
of biological networks and pathways.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ated solely by thyroid hormones (THs) and this important
postembryonic developmental period can be divided into
three specific stages: premetamorphosis, prometamorpho-
sis and metamorphic climax, characterized in part by TH
status [2]. Premetamorphosis is the period after em-
bryogenesis in which free-living tadpoles increase in
size in the absence of THs. During prometamorphosis,
endogenous TH levels start to increase, causing mor-
phological changes such as the growth of the hind
limbs. Metamorphic climax is characterized by the
highest level of THs and drastic morphological changes
including the complete resorption of the tail and the
formation of a stomach.
Metabolomics is the comprehensive analysis of the
whole metabolome (metabolite profiles) under a given set
of conditions [3] and is a burgeoning field that has started
to play a crucial role in systems biology and personalized
medicine [4,5]. Metabolomics differs from other "omics"
tools in many ways. The metabolome directly represents
the phenotype unlike the genome, transcriptome or prote-
ome, the dynamic range is much wider, and the metabo-
lome is far more chemically heterogeneous and complex,
thereby producing large, complex datasets that require
rigorous computational and statistical analyses [6,7].
Despite these challenges, the direct link of the metabo-
lome to the phenotype is an advantage because genomic
or transcriptomic changes may or may not affect the
protein level, and proteomic changes may or may not
affect metabolites [8].
To our knowledge, no comprehensive metabolomic
study has yet been conducted on metamorphosis [9].
We applied a global, mass spectrometry (MS)-based
metabolomics approach, using ultra-performance liquid
chromatography (UPLC) coupled to a quadrupole time-
of-flight (Q-TOF) mass spectrometer, to identify metab-
olites in serum samples from Rana catesbeiana (North
American bullfrogs) at different postembryonic develop-
mental stages: from tadpoles to froglets. Serum was the
tissue of choice to provide an overall view of the dynamic
changes experienced by the frog tadpole and enable the
identification of metabolites involved in the coordin-
ation of metamorphic processes throughout the tadpole.
R. catesbeiana were used in the present study because
of their large size enabling the analysis of serum from
individual animals, their world-wide distribution and
availability, and their genetic diversity and life history
resemble that of humans more closely than other la-
boratory frog species [9,10]. In fact, anuran metamor-
phosis is developmentally equivalent to postembryonic
organogenesis in mammals [11]. Both systems share
considerable similarities in general processes (cell pro-
liferation, differentiation, and apoptosis), biochemical
and molecular events (a switch from fetal/larval to adulthemoglobin in red blood cells, skin keratinization, and
urea cycle enzyme induction) and, most strikingly, the
developmental progression of structures and functions
in the central and peripheral nervous system [2,11].
We show herein that substantial fluctuations in metab-
olite abundance and extensive remodelling in metabolic
pathways occur during R. catesbeiana metamorphosis.
In particular, we observed metabolites with a significant
abundance change in urea cycle, arginine and nucleotide,
cysteine/methionine and lipid metabolism pathways sug-
gesting prominent roles of these pathways in the coordin-
ation of the metamorphic process.
Results and discussion
To discover metabolites with differential abundance
patterns and to investigate the developmental changes
in the metabolic pathways of R. catesbeiana during
metamorphosis, R. catesbeiana tadpoles were divided
into seven different developmental stage ranges based
on Taylor and Kollros [12] (TK) stages: VI–X, XII–XV,
XVI–XVII, XVIII, XIX–XX, XXI–XXII, and > XXV.
Twelve samples, each from an individual animal, were
prepared for each range, yielding 84 samples in total.
Serum samples from these tadpoles were obtained by
dissection, and to gain a comprehensive overview of
the profile of metabolites, two types of extracts were
prepared for the subsequent MS analyses: "total" (ca.
90% acetonitrile) extracts favoring nonpolar metabo-
lites (using reversed-phase chromatography) and aque-
ous extracts for polar metabolites (using hydrophilic
interaction liquid chromatography). Total extracts were
prepared by complete deproteinization of serum sam-
ples. For aqueous extracts, liquid-liquid-extraction was
performed after deproteination, and the aqueous layer
was used. UPLC-MS data acquisition was performed in
both electrospray ionization (ESI) positive and negative
mode, producing four different datasets: total extract
ESI-(+) (Tot+), total extract ESI-(–) (Tot-), aqueous ex-
tract ESI-(+) (Aqu+) and aqueous extract ESI-(–) (Aqu-).
After preprocessing of the raw UPLC-MS data, major
peaks were detected and integrated. These peak area
values represented the abundance of metabolites and
were used for data analysis. To detect differentially-
produced metabolites, the Kruskal-Wallis test was per-
formed, and the p-values were corrected by controlling
the false discovery rate (FDR). As a stringent criterion,
a significance level of 0.001 was used. To tentatively as-
sign structures to these metabolites, the metabolite
masses were searched using MassTRIX database search
software as described in the Materials and Methods.
The identities (IDs) of selected metabolites were con-
firmed by running authentic standards and by compar-
ing their masses, chromatograms, MS spectra, and
retention times.
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correlation of their abundance patterns with
morphometrics
A total of 4528 metabolite features were detected in at
least one of the four datasets, although some metabolites
were observed in more than one dataset (Table 1). Despite
the stringent significance level (α = 0.001 after p-value ad-
justment), 3329 metabolite features (74%) showed signifi-
cant abundance changes during metamorphosis (Table 1),
highlighting the dynamic remodelling of metabolic path-
ways during bullfrog metamorphosis. A larger number of
metabolites were detected in total extracts than in aque-
ous extracts because of the existence of a large number of
lipophilic molecules, which is consistent with the human
serum metabolome profile [13]. Of the metabolite features
with significant abundance changes, 655 of them were
assigned putative IDs and 89 of them were confirmed by
running authentic compounds (Table 2).
For each dataset, Principal Component Analysis was
performed for those metabolites which showed significant
abundance changes to determine how the metabolite
abundance patterns correlate with the developmental
stages of the animals from which the metabolites were
extracted. The PCA plots using data from 12 individual
tadpoles per group (Figure 1) showed distinct sub-
groups of scores, which corresponded to the different
developmental stages. Developmental staging was based
upon morphological criteria [12], and the data demon-
strate that TK VI-X and XII-XV and froglets are readily
distinguishable groups based upon metabolite features
(Figure 1). TK XVI-XVII and XVIII tended to group to-
gether as late prometmorphs while a clearer progression
from TK XIX-XX (start of metamorphic climax) to XXI-
XXII (mid-metamorphic climax) was evident (Figure 1).
This further sharpens the resolution of the distinction
between postembryonic developmental stages. Since
the clusters of the scores representing the froglet
stage (TK > XXV) were isolated compared to other TK
stage score clusters, the metabolic profile of froglets is
more distinct than that of any tadpole at any previous









Total RP ESI+ Tot+ 2129
Total RP ESI– Tot- 1286
Aqueous HILIC ESI+ Aqu+ 693
Aqueous HILIC ESI– Aqu- 420
Total 4528
aTotal extracts were prepared by complete deproteinization of serum samples and
metabolites. Aqueous extracts were prepared by liquid-liquid-extraction of deprotei
liquid chromatography (HILIC) column to select for polar metabolites. After statistic
against MassTRIX database to obtain putative IDs. Subsequently, the IDs of selectedA box plot of log2 transformed peak areas versus TK
stage ranges was created for each metabolite, and the
abundance pattern produced was inspected. In total, 13
different metabolite abundance patterns were consist-
ently observed in the datasets (Figure 2). These patterns
show how tightly metabolites are regulated during meta-
morphosis. The frequency of these patterns was counted
and tabulated (Table 3), and the top three most common
classifiable patterns were: a significant decrease at the
froglet stage (pattern = Figure 2D), a significant increase
around the metamorphic climax and a return to basal
level (pattern = Figure 2G), and a significant increase at
metamorphic climax followed by a significant decrease
at the froglet stage (pattern = Figure 2I). A significant de-
crease in the abundance of metabolites at the froglet
stage accentuates how metabolically different the frog is
compared to larvae upon completion of metamorphosis.
A significant increase at the metamorphic climax corre-
lates with the circulating level of THs [14]. These abun-
dance patterns imply that the metamorphic climax is
where a large fraction of metabolites exhibit an abun-
dance change in anticipation of drastic morphological
changes.
Intriguingly, we observed some metabolites that showed
a statistically significant variation in abundance patterns.
For example, the abundance of the metabolite shown in
Figure 2M dropped significantly at the froglet stage and
also showed a large variation (heteroscedasticity). Changes
in variation were also observed in our previous study [15],
and poses interesting biological questions: what is causing
such wide variation, what are the effects, and what is the
significance of such a phenomenon? When scientists per-
form statistical tests, they commonly look for significant
differences among data, but significant variation in data
also may provide important insights.
Remodelling of core metabolic pathways during
metamorphosis
The MassTRIX database search generated KEGG pathway
maps in which the locations of query metabolites were







1648 (77%) 336 16
1072 (83%) 212 13
291 (42%) 43 27
318 (76%) 64 33
3329 (74%) 655 89
were chromatographed on a reversed-phase (RP) column to select for nonpolar
nized serum extracts and were chromatographed on a hydrophilic interaction
al analysis, metabolites with significant abundance changes were searched
metabolites were validated by running standards.
Table 2 Reagents used for the validation of selected metabolites
Metabolite Chemical Company Product
number
MW
1-Methyl-Histidine 1-Methyl-L-Histidine Sigma-Aldrich 67520-50MG 169.18
Arachidonic acid Arachidonic acid sodium salt Sigma-Aldrich A8798-5MG 326.45
Arginine L-Arginine Sigma-Aldrich A5006-100G 174.2
C18 Sphinganine D-erythro-sphinganine Avanti Polar Lipids 60498P 301.51
C18 Sphinganine 1-Phospahte D-erythro-sphinganine-1-phosphate Avanti Polar Lipids 860536P 381.488
CDP Cytidine 5′-Diphosphate MP Biomedicals 0215075810 469.124
C24:1 Dihydroceramide N-nervonoyl-D-erythro-sphinganine Avanti Polar Lipids 860629P 650.113
Cer(d18:1/17:0) N-heptadecanoyl-D-erythro-sphingosine Avanti Polar Lipids 860517P 551.927
Ceramide (d18:1/16:0) N-palmitoyl-D-erythro-sphingosine Avanti Polar Lipids 860516P 537.901
C24:1 Ceramide N-nervonoyl-D-erythro-sphingosine Avanti Polar Lipids 860525P 648.097
CerP(d18:1/8:0);
C8 Ceramide-1-Phosphate
N-octanoyl-ceramide-1-phosphate (ammonium salt) Avanti Polar Lipids 860532P 522.698
cis-Aconitate trans-Aconitic Acid TCI America A0127 174.11
Citrulline L-Citrulline Sigma-Aldrich C7629-1G 175.19
CMP Cytidine 5′-Monophosphate Disodium Salt Sigma-Aldrich C1006-500MG 367.16
Creatine Creatine MP Biomedicals 0210142225 149.1
Cystathionine L-Cystathionine Sigma-Aldrich C7505-10MG 222.26
Cysteine L-Cysteine Sigma-Aldrich W326305-100G 121.16
Deoxyinosine 2′-Deoxyinosine MP Biomedicals 02101490.1 252.2
dGMP 2′-Deoxyguanosine-5′-Monophosphate Disodium Salt Hydrate MP Biomedicals 02100561.2 391.2
Dopamine 3-Hydroxytyramine Hydrochloride TCI America A0305 189.64
Ethanolamine phosphate O-Phosphorylethanolamine Sigma-Aldrich P0503-1G 141.06
Glutamine L-Glutamine Sigma-Aldrich G3202-100G 146.14
Guanine Guanine Sigma-Aldrich G11950-10G 151.13
Guanosine Nucleosides Test Mix Sigma-Aldrich 47310-U 283.24
Palmitate Palmitic acid Sigma-Aldrich P0500-10G 256.42
Histidine L-Histidine Sigma-Aldrich H8000-25G 155.15
Homocitrulline L-Homocitrulline Santa Cruz Biotechnology sc-269298 189.21
Homocysteine DL-Homocysteine Sigma-Aldrich H4628-10MG 135.18
Homoserine L-Homoserine TCI America H1030 119.12
Hydroxyproline trans-4-Hydroxy-L-proline Sigma-Aldrich H54409-100G 131.13
Hypoxanthine Hypoxanthine Sigma-Aldrich H9377-25G 136.11
Inosine Nucleosides Test Mix Sigma-Aldrich 47310-U 268.23
Carnitine L-Carnitine hydrochloride Sigma-Aldrich C0283-5G 197.66
L-DOPA L-β-3,4-Dihydroxyphenyl-Alanine MP Biomedicals 02101578.2 197.19
Linoleic acid Linoleic acid sodium salt Sigma-Aldrich L8134-100MG 302.43
Lysine L-Lysine Sigma-Aldrich L5501-25G 146.19
Methionine L-Methionine Sigma-Aldrich M9625-25G 149.21
N-Acetyl-L-Aspartate N-Acetyl-L-Aspartic Acid Sigma-Aldrich 00920-5G 175.14
N-Arachidonoyldopamine N-Arachidonoyl Dopamine Cayman Chemical 90057 439.6
Nicotinamide Nicotinamide Sigma-Aldrich 72340-100G 122.12
Norvaline DL-Norvaline Sigma-Aldrich N7502-100G 117.15
Acetylcarnitine O-Acetyl-L-carnitine hydrochloride Sigma-Aldrich A6706-5G 239.7
Octadecenoic acid Oleic acid Sigma-Aldrich O1008-1G 282.46
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Table 2 Reagents used for the validation of selected metabolites (Continued)
Oleoylcarnitine Oleoyl-L-carnitine hydrochloride Sigma-Aldrich 597562 462.11
Ornithine L-Ornithine Dihydrochloride TCI America O0089 205.08
Pantothenate D-Pantothenic acid hemicalcium salt Sigma-Aldrich P2250-5G 238.27
Proline L-Proline Sigma-Aldrich P0380-100G 115.13
Riboflavin (−)-Riboflavin Sigma-Aldrich R7649-25G 376.36
S-Adenosylhomocysteine S-(5′-Adenosyl)-L-homocysteine Sigma-Aldrich A9384-10MG 384.41
Sphingosine 1-phosphate Sphingosine 1-Phosphate Sigma-Aldrich S9666-1MG 379.47
Taurine Taurine Sigma-Aldrich T0625-10G 125.15
trans-Cinnamate trans-Cinnamic acid Sigma-Aldrich W228818-1KG-K 148.16
Trimethylglycine Betaine aldehyde chloride Sigma-Aldrich B3650-2MG 137.61
Trimethyllysine Nε,Nε,Nε-Trimethyllysine hydrochloride Sigma-Aldrich T1660-25MG 224.73
Tyrosine L-Tyrosine Sigma-Aldrich T3754-50G 181.19
Uridine Nucleosides Test Mix Sigma-Aldrich 47310-U 244.2
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http://www.biomedcentral.com/1471-213X/14/5reconstructed metabolic pathway maps for the metabolites
found in the present study which showed significant abun-
dance changes. To depict the abundance changes of me-
tabolites for each pathway relative to the premetamorphic
stage at subsequent developmental stages, the direction



























































































































































Figure 1 PCA score plots of the metabolites that showed significant a
metabolites with statistically significant abundance changes (determined b
components were plotted. The percentages indicate the amount of variatio
correspond to the TK stages at which the serum samples were taken from
XVIII, E = TK XIX–XX, F = TK XXI–XXII, and G = > XXV. The score plots showe
morphological measures (TK staging). (A) Tot+ dataset. (B) Tot- dataset. (C)illustrated using the colour scheme shown in Figure 3.
Several components within the pathways outlined below
were detected, some of which remain constant throughout
this developmental period. We highlight below those me-
tabolites and pathways for which validation with authentic







































































































































































bundance changes. For each dataset, PCA was performed on
y corrected p-values) and the first (PC1) and second (PC2) principal
n accounted for by each of these two components. The letters
tadpoles as follows: A = TK VI–X, B = TK XII–XV, C = TK XVI–XVII, D = TK
d association between metabolite abundance change and the
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M
Figure 2 Distinct metabolite abundance patterns that were consistently observed in the datasets. After inspecting the abundance
patterns of individual metabolites, a total of 13 different expression patterns were observed in the datasets consistently. The frequency of the
observed patterns is tabulated in Table 3. (A) Monotonic ↑. (B) Monotonic ↓. (C) ↑ at the froglet stage (TK > XXV). (D) ↓ at the froglet stage
(TK > XXV). (E) ↓ after the premetamorphic stage (TK VI–X). (F) ↑after the premetamorphic stage (TK VI–X). (G) ↑ at the metamorphic climax
(TK XXI–XXII) then return to a basal level. (H) ↓ at the metamorphic climax (TK XXI–XXII) then return to a basal level. (I) ↑ at the metamorphic
climax (TK XXI–XXII) followed by ↓ at the froglet stage (TK > XXV). (J) ↓ at the metamorphic climax (TK XXI–XXII) followed by ↑ at the froglet stage
(TK > XXV). (K) Significant abundance change at the metamorphic climax, and the abundance remains constant at the froglet stage. (L) Step-wise
↑ or ↓. (M) Significant variation (significant unequal variance determined by the Levene’s test, padj < 0.01).
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The metabolic pathways for the urea cycle, arginine and
purine/pyrimidine metabolism are linked to each other
and many of the metabolites showed significant abun-
dance changes during metamorphosis (Figure 4) with a
general pattern of increase in abundance around the
metamorphic climax, followed by a decrease at the frog-
let stage relative to the premetamorphic TK VI-X group
(Figure 3B).The remodelling of the nucleoside and nucleotide me-
tabolism pathways reflects the essential roles of nucleo-
sides and nucleotides in not only being components of
DNA and RNA but also in energy metabolism. Nucleo-
side di- and triphosphates are substrates for ligases as
well components of coenzymes [16]. As such, increased
biosynthesis of ribonucleotides has been observed in
tadpole liver [17,18]. It is therefore likely that the differ-
ential pattern of nucleotide metabolic pathways implies
Table 3 Frequency of the thirteen different abundance patterns that were consistently observed in the datasets
Corresponding
graph in Figure 2
Number of metabolites (% of total)
Pattern Tot+ Tot- Aqu+ Aqu-
Monotonic ↑ A 9(0.4) 4(0.3) 3(0.4) 7(1.7)
Monotonic ↓ B 22(1.0) 33(2.6) 16(2.3) 6(1.4)
↑ at froglet C 79(3.7) 66(5.1) 5(0.7) 7(1.7)
↓ at froglet D 438(20.6) 286(22.2) 86(12.4) 125(29.8)
↓ after premetamorphosis E 39(1.8) 16(1.2) 15(2.2) 3(0.7)
↑ after premetamorphosis F 125(5.9) 17(1.3) 6(0.9) 8(1.9)
↑ at metamorphic climax then return to a basal level G 293(13.8) 170(13.2) 30(4.3) 41(9.8)
↓ at metamorphic climax then return to a basal level H 155(7.3) 107(8.3) 16(2.3) 2(0.5)
↑ at metamorphic climax then ↓ at froglet I 233(10.9) 159(12.4) 7(1.0) 9(2.1)
↓ at metamorphic climax then ↑ at froglet J 90(4.2) 44(3.4) 5(0.7) 1(0.2)
↑ or ↓ at metamorphic climax then constant K 31(1.5) 17(1.3) 4(0.6) 5(1.2)
Step-wise ↑ or ↓ L 71(3.3) 43(3.3) 4(0.6) 3(0.7)
Unclassified 544(25.6) 324(25.2) 496(71.6) 203(48.3)
Total 2129 1286 693 420
Unequal variationa M 94(4.4) 36(2.8) 0(0) 4(1)
aUnequal variation was detected by Levene’s test (padj < 0.01). Therefore the abundance patterns in this group include patterns from A to L.
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metamorphosis and tissue remodelling.
During metamorphosis, tadpoles undergo a fasting period
during which energy is provided by muscle breakdown of
the tail [19,20]. Creatine acts as an energy shuttle of ATP
between the mitochondrial sites of ATP production and the
cytosolic sites of ATP utilization [21]. 3-methylhistidine
has been shown to be a marker of muscle breakdown [22].p < 0.05  
p  > 0.05  




































Figure 3 The progression of abundance changes of metabolites. In th
change relative to the premetamorphic stage was illustrated using three co
(significant decrease).Both creatine and 3-methylhistidine showed a significant
decrease at the froglet stage (Figures 3, 5 and 6), which
correlates with the energy requirement of tadpoles during
metamorphosis.
The significant changes in the abundance patterns of
the metabolites in the urea cycle and arginine metabol-
ism pathways are consistent with the extensive hepatic








e metabolic pathways examined in the present study, the abundance






































































































Figure 4 Significant abundance changes of the metabolites in the urea cycle, arginine and purine/pyrimidine metabolism pathway.
(A) Overall abundance changes of the metabolites. Black circles indicate a significant (padj < 0.001) abundance change at at least one
developmental stage range during metamorphosis. Grey circles indicate a nonsignificant abundance change, and white circles indicate the
metabolites were not detected. (B) Progression of the abundance change of the metabolites relative to the premetamorphic stage (TK VI–X). The
abundance levels of each metabolite at other TK stage ranges were compared to the abundance level at the premetamorphic stage (αadj = 0.05).
The metabolites are depicted as follows: significant ↑ (red); significant ↓ (blue); nonsignificant change (grey); and not observed (white).
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http://www.biomedcentral.com/1471-213X/14/5ammonotelic larva to a ureotelic frog. At premetamorphic
stages, anuran tadpoles excrete 90% of their nitrogen as
ammonia [23,24], but nitrogen excretion shifts to urea
rather than ammonia at metamorphic climax, and urearepresents 78% of nitrogenous waste in postmetamorphic
frogs [23-25]. This transition is accompanied by the ac-
tivation of the urea cycle enzymes: carbamyl phosphate































































































































































































































































Figure 5 Boxplots of metabolites in urea cycle, arginine and purine/pyrimidine metabolism pathway.




















































































Figure 6 Boxplots of metabolites that were not included in
any pathways.
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differential expression of these enzymes during metamor-
phosis has been well-characterized [27-30]. Arginine, cit-
rulline, and ornithine all showed a significant decrease at
the froglet stage. Since these urea cycle enzymes work in a
concerted manner [30] and several intermediates contrib-
ute to other metabolic pathways, it is difficult to predict
the abundance patterns of urea cycle metabolites in the
serum at specific developmental stages.
Homocitrulline was also observed in the data, and its
abundance pattern continued to decrease until TK XXI–
XXII, after which there was a slight increase at the froglet
stage (Figures 3 and 5). A high level of homocitrulline
in humans is associated with defects in the urea cycle,
in particular with hyperammonemia, hyperornithinemia,
homocitrullinuria (HHH) syndrome which is caused the
deficiency of ornithine translocase, a transporter of orni-
thine into the mitochondria [31]. Without ornithine in the
mitochondria, carbamoyl phosphate condenses with lysine
to form homocitrulline. HHH syndrome is characterized
by elevated plasma ornithine and ammonia levels [32].
This human disease resembles the abundance profile of
ornithine found in the present study, namely an elevated
level of ornithine during ammonotelic larval stages, and it
is possible that the production of homocitrulline in tad-
poles is due to the lack of a functional urea cycle, resulting
in conditions similar to HHH syndrome.
Arginine is one of the most versatile amino acids,
serving as a precursor for the synthesis of protein, nitric
oxide (NO), creatine, citrulline, ornithine, and urea [33].
Of particular note is arginine’s role as a substrate in NO
synthesis. NO is a radical produced from arginine byNO synthase, and this synthesis occurs in virtually all
mammalian cells and tissues [34]. NO has been increas-
ingly recognized as an important neurotransmitter and
neuromodulator and has been implicated in various
physiological roles in the central nervous system including
nociception and olfaction [35,36], fatty acid oxidation and
glucose uptake [34], as well as the release of other neu-
rotransmitters such as norepinephrine and dopamine
[37]. In R. catesbeiana, NO modulates the respiratory
motor activity and enhances the lung burst activity
[38,39]. In neurons, NO is synthesized by glutamate ac-
tivation of N-methyl-D-aspartate (NMDA) receptors
[40,41]. In addition to the activation of NMDA recep-
tors to produce NO, glutamate is the major excitatory
neurotransmitter with known functions in opening ion
channels and stimulating inositol phospholipid cycle
[42,43] and the formation of cGMP [44,45]. Glutamate
was observed in our data (Figures 3 and 5), and it exhib-
ited a significant differential abundance pattern with
maximal levels at the metamorphic climax followed by a
sharp decrease, a pattern similar to that found by Wiggert
and Cohen [46], suggesting a higher demand for glutamate
at the metamorphic climax.
Cysteine/methionine metabolism pathway
Metabolites in the cysteine/methionine metabolism path-
way showed a general decreasing pattern until the froglet
stage (Figures 7 and 8). Both cysteine and methionine are
important antioxidant in biological systems. Cysteine is a
substrate for the formation of glutathione, and methionine
acts as an endogenous antioxidant in proteins [47]. An-
other important aspect of this metabolic pathway is the
production of S-adenosylmethionine (SAM), the principal
biological methyl donor. Upon methyl group transfer,
SAM is converted to S-adenosylhomocysteine (SAH), and
the SAM/SAH ratio is considered to be an indicator of
cellular methylation capacity [48]. Methylation plays crit-
ical roles in epigenetics, reprogramming, and cancer, and
histone methylation has been shown to regulate the action
of TH receptor (TR) in Xenopus tropicalis upon T3 treat-
ment [49,50]. SAM was not detected in the present study,
but SAH was detected, and its abundance dropped dra-
matically at the froglet stage. SAH inhibits the action of
most SAM-dependent methyltransferases, and it has
been suggested that metabolite modulation of DNA
methyltransferases occurs mainly through SAH in many
cell types [51].
Trimethyllysine found in the present study suggests the
importance of histone methylation during metamorphic
reprogramming. Among the possible histone modifica-
tions, methylation represents a complex type of modifica-
tion that targets primarily histone H3, in which arginine
and lysine residues can be mono-, di-, or trimethylated
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Figure 7 Significant abundance changes of the metabolites in
the cysteine/methionine metabolism pathway. (A) Overall
abundance changes of the metabolites. (B) Progression of the
abundance change of the metabolites relative to the
premetamorphic stage (TK VI–X). Refer to Figure 4 legend for details.
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http://www.biomedcentral.com/1471-213X/14/5metamorphosis has been demonstrated – Matsuura et al.
[50] showed that TRs induce histone modifications to ac-
tivate transcription during larval intestinal cell death, and
adult stem cell development in X. tropicalis, and Bilesimo
et al. [49] observed gene and tissue-specific patterns of
histone methylation upon TH treatment of premeta-
morphic X. tropicalis tadpoles in the tail fin and the brain.
TH treatment decreased the level of a repressive marker,
Me3H3K27, and increased the level of an activation
marker, Me3H3K79, thereby initiating transcription of TH
target genes in X. tropicalis intestine [50] and tail fin [49].
Interestingly, both SAH and trimethyllysine showed similar
abundance patterns - a decrease until TK XVII, followedby an increase until TK XXI–XXII, and then a sharp de-
cline at the froglet stage (Figures 7 and 8).
Trimethyllysine is also a precursor of carnitine and
acetylcarnitine. Carnitine acts as a shuttle to transport
long-chain fatty acids from the cytosol into the mitochon-
dria during lipid catabolism for the generation of meta-
bolic energy [53], and both carnitine and acetylcarnitine
showed a general increase at the metamorphic climax
(Figures 7 and 8), suggesting increased lipid mobilization
at this time in development.
Taurine, a precursor of taurocholate, exhibited con-
stant levels throughout development with a significant
decrease at the froglet stage (Figures 7 and 8). Taurine
has many roles in metabolism such as osmoregulation,
modulation of Ca2+ dependent processes, and antioxida-
tion [54]; however, the significance of the regulation of
this metabolite is not clear.
Lipid metabolism
Most lipid molecules were detected in the total metabolite
extracts, and phospholipids were predominant, which is
consistent with the human metabolome profile [55]. How-
ever, a large number of structural isomers are possible for
each lipid metabolite, so we were only able to identify lipid
classes (Table 4 and Figure 9). Each lipid class showed
specific abundance patterns, but the most common
abundance pattern for these lipid metabolites was a
sharp drop at the froglet stage (Table 4 and Figure 9).
Little is known about lipid metabolism during frog
metamorphosis. Triglycerides (TG) constitute the majority
of the fat body in anurans [56], and TG was the most
common among the lipid metabolites identified in the
present study (Table 4). Interestingly, many of these lipids
showed two common abundance patterns: a decrease after
the metamorphic climax or an increase until the meta-
morphic climax followed by a decrease (Figure 9). A study
by Sawant and Varute [57] showed a similar lipid profile
in R. tigrina, in which the total lipid and TG concentra-
tions also increased until the metamorphic climax
followed by a sharp decrease. This trend may be due to
increased mobilization of lipids during metamorphosis
to provide the energy required for the remodelling of
organs and tissues as the animals progress to a state at
the metamorphic climax, where they cease to eat until
metamorphosis is completed. The known effects of THs
on lipid metabolism include enhanced catabolism and
an increase in the synthesis and mobilization of TGs
stored in adipose tissue [58,59], and the detection of
carnitine and acetylcarnitine, as shown in the cysteine/
methionine metabolism pathway, corroborates this idea.
Another interesting observation was the discovery of
62 phosphatidylserine (PS) forms (structural isomers
could not be differentiated) of which 48% showed a sig-




































































































































































Figure 8 Boxplots of metabolites in the cysteine/methionine metabolism pathway.
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Triglyceride TG 79 ↓ at froglet
Diglyceride DG 13 ↑ at climax then
↓ at froglet
Phosphatidic acid PA 36 ↓ at froglet
Phosphatidylcholine PC 27 ↓ at froglet
Phosphatidylethanolamine PE 18 ↓ at froglet
Phosphatidylglycine PG 29 ↑ at climax
Phosphatidylserine PS 62 ↓ at froglet
Phosphatidylinositol PI 28 ↓ at froglet
Most of these lipid metabolites were found in Tot+ or Tot-. For many lipid
metabolites, structural isomers were possible, therefore only the type of the
lipid molecule (e.g. TG) was used as the ID.
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http://www.biomedcentral.com/1471-213X/14/5and Figure 9). PS accounts for 5-20% of the total phos-
pholipids in the cell membrane and is located on the
inner leaflet of the lipid bilayer [60]. PS on the surface
of red blood cells is a biomarker for apoptosis [61] as the
appearance of PS on the cell surface serves as a mechan-
ism for macrophages to recognize apoptotic cells due to
changes in surface hydrophobicity. As macrophages in-
crease in number at the metamorphic climax, it is likely
that an abundance change of PS may correlate with the
extent of apoptosis occurring during metamorphosis in
R. catesbeiana.
Despite the possibility of a large number of structural
isomers, we were able to identify the key metabolites in
the sphingolipid metabolism pathway (Figures 10 and 11)
by comparing them to authentic compounds because the
database search yielded either one or a few hits for these
metabolites. What is unique about the sphingolipid me-
tabolism pathway is that the metabolites in this ubiquitous
evolutionarily conserved pathway are implicated in various
signal transduction pathways and, unlike the classical
cAMP signalling cascade, the sphingolipid metabolism
pathway is more complex because enzymes are intimately
related to each other, the metabolites are recycled in the
pathway, and interconversions are common [62].
The two key metabolites of the pathway are ceramide
and sphingosine 1-phosphate (S1P). These two metabolites
have been known to exert opposing effects in biological
systems - ceramide promotes senescence, differentiation,
apoptosis and cell-cycle arrest whereas S1P induces prolif-
eration, mitogenesis, inflammation, migration, angiogen-
esis, and protection from apoptosis [63]. We were able to
identify three ceramides with different chain lengths: C16,
C17 and C24:1 (Figure 10). The pathway begins with the
condensation of serine and palmitoyl-CoA, generated
from palmitate, a C-16 fatty acid, and C16 ceramide is
the most predominant form of ceramides and has been
shown to induce activation-induced cell death in Ramos
B-cells [64].S1P and the kinases that produce it have emerged as
crucial regulators of numerous biological processes [13]
and their actions are evolutionarily conserved [62]. S1P
is produced by sphingosine kinase and is a ligand for
five G-protein-coupled receptors leading to activation
or inhibition of downstream enzymes in numerous sig-
nalling pathways including extracellular signal-related
kinase (ERK), Jun amino terminal kinase (JNK), the
small GTPases of the Rho family (Rho and Rac), phospho-
lipase C (PLC), adenyl cyclase-cyclic AMP, and phos-
phatidylinositol 3-kinase (PI3K) [62]. S1P also promotes
cell migration, angiogenesis, calcium homeostasis, and
DNA synthesis, and it is highly likely that this metabolite
plays crucial roles during remodelling in metamorphosis
[62,65]. Though not as well-studied as S1P, ceramide 1-
phosphate (C1P) has also been reported to promote mito-
genesis and block apoptosis [66].
The progressive changes in the abundance of metabo-
lites in the sphingolipid metabolism pathway did not show
a clear pattern, and this might be because of the recycling
and interconversion of the metabolites in this pathway.
C17 ceramide levels decreased significantly at the froglet
stage whereas C16 and C24:1 ceramides showed a signifi-
cant increase at the froglet stage (Figures 10 and 11). S1P
level showed an increase around the metamorphic climax,
peaking at TK XXI–XXII, followed by a sharp decrease at
the froglet stage. This pattern, resembling that of circulat-
ing TH levels, also supports the possible role of S1P as an
important regulator of metamorphosis, as most drastic
remodelling occurs at the metamorphic climax.
Eicosanoid metabolism pathway
Arachidonic acid-derived eicosanoids, including prosta-
glandins (PG) and leukotrienes (LT), act as signalling
molecules that control diverse biological responses such
as vascular homeostasis and inflammatory responses to
tissue remodelling [67]. The metabolites in the eicosa-
noid metabolism pathway showed a significant abun-
dance change (Figures 12 and 13). PG A, B, C, and J2
could not be distinguished because they are structural
isomers. Similarly, other groups of metabolites were
indistinguishable including PG D, E, H2, LTB4, and 20-
OH-LTB4. Anurans have substantially different immune
systems at the larval and frog stages [68]. It has been hy-
pothesized that the development of molecules specific
to the frog stage (adult hemoglobin, adult-type keratin,
the urea cycle enzyme L-arginase, etc.) could elicit self-
destructive immune responses during metamorphosis
[69]. To avoid this, amphibians self-destruct their lympho-
cytes [68], which is supported by the fact that amphibian
metamorphosis is not characterized by autoimmune tissue
destruction. In Xenopus laevis, a decline in lymphocytes
during metamorphosis has been observed in the spleen,
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Tot TG(16:0/16:0/20:4) RT = 21.36+Tot TG(16:0/20:0/20:4) RT = 20.98+ Tot+ DG(21:0/22:2/0:0) RT = 22.02 Tot+ DG(18:2/22:6/0:0) RT = 18.59
Tot+    PA(22:1/22:4)    RT = 17.67 Tot+   PA(P-16:0/16:1)   RT = 16.34 Tot- PC(O-12:0/O-2:0) RT = 12.62 Tot+ PC(22:0/P-18:0) RT = 20.41
85.91=TR)1:22/0:91(GP+toT96.91=TR)2:22/0:02-P(GP-toT34.71=TR)6:22/2:81(EP-toT
Tot-  PS(13:0/22:4)  RT = 18.15 Tot-  PS(16:0/16:0)  RT = 19.12 Tot-   PI(17:0/22:1)   RT = 20.29 Tot+  PI(O-16:0/20:1)  RT = 18.07
Tot-    PE(18:2/P-18:1)    RT = 19.1
TK Stage
Figure 9 The two most common abundance patterns for the lipid classes observed. Each lipid class exhibited common abundance
patterns, and the two most common abundance patterns are presented. In each graph, the percentage values correspond to the fraction of
lipids that exhibited the abundance pattern of the graph. In most lipid classes, the most common abundance pattern was a drop at the froglet
stage. “O-“, alkyl ether linkage; “P-“, (1Z)-alkenyl ether (neutral plasmalogen) species.
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TK XIX-XX TK XXI-XXII TK >XXV
Figure 10 Significant abundance changes of the metabolites in
the sphingolipid metabolism pathway. Glucosylceramide (GlcCer)
and galactosylceramide (GalCer) are structural isomers and hence
cannot be differentiated, but both metabolites are converted to
distinct metabolites, so they are depicted separately. The divided
circles indicate variants of that metabolite (different chain length)
were detected. Abbreviations: GalCer: galactosylceramide, GlcCer:
glucosylceramide, LacCer: lactosylceramide, SM: sphingomyelin.
(A) Overall abundance changes of the metabolites. (B)
Progression of the abundance change of the metabolites relative
to the premetamorphic stage (TK VI–X). Refer to Figure 4 legend
for details.
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namic change in the eicosanoid metabolism pathway that
occurs during metamorphosis.
Eicosanoids play an integral role in immunity, differenti-
ation, cell proliferation, migration, and antigen presenta-
tion [67], and arachidonic acid is the central molecule thatgives rise to other eicosanoids [72]. Arachidonic acid
induces apoptosis [73,74] and the maximal level at the
metamorphic climax suggests a possible role of arachi-
donic acid in tissue remodelling during metamorphosis.
Hydroxyeicosatetraenoic acid (HETE) and hydroperoxyei-
cosatetraenoic acid (HPETE), also products of arachidonic
acid formed during inflammation, regulate angiogenesis
[75]. HETE promotes angiogenesis whereas HPETE in-
hibits angiogenesis. Arachidonic acid levels increased
significantly, peaking at the metamorphic climax and
decreasing significantly at the froglet stage (Figures 12
and 13). HETE showed a significant decrease after the
premetamorphic stage, increasing gradually until the meta-
morphic climax, then dropping significantly at the froglet
stage (Figures 12 and 13). HPETE remained constant and
increased at the metamorphic climax, and the increased
level remained at the froglet stage (Figures 12 and 13).
The role of HETE and HPETE in angiogenesis also implies
a role in tissue remodelling during metamorphosis. The
differential abundance patterns of these two metabolites
(Figures 12 and 13) suggest they may work in a concerted
manner for vascularization throughout metamorphosis.
In addition to the eicosanoid metabolism pathway,
we detected tyrosine, L-3,4-dihydroxyphenylalanine (L-
DOPA), dopamine, and N-arachidonoyldopamine (NADA)
(Figures 12 and 13). Tyrosine did not show a significant
abundance change. The abundance of L-DOPA dropped
significantly at TK XIX–XX until the froglet stage. L-
DOPA is a precursor for catecholamines including dopa-
mine, norepinephrine, and epinephrine that are implicated
in various physiological processes and the hormonal con-
trol of metamorphosis, and the dropping level of L-DOPA
around metamorphic climax may indicate the requirement
of L-DOPA to synthesize catecholamines to execute
metamorphosis. Dopamine showed a pattern of a gen-
eral increase around the metamorphic climax followed
by a decrease at the froglet stage (Figures 12 and 13).
This pattern may be explained by the role of dopamine
as an inhibitor of the release of prolactin (PRL), an
antimetamorphic hormone [76]. It has been suggested
that the role of PRL is to counteract high concentra-
tions of THs at the metamorphic climax to coordinate
the subsequent transformations of organs and tissues.
The inhibitory effect of dopamine on PRL release may
be another way of controlling the circulating level of
THs in order to tightly regulate the completion of
metamorphosis. The levels of tyrosine did not change
significantly during metamorphosis. Tyrosine is a pre-
cursor for the synthesis of THs in the thyroid gland,
but we did not detect T3 or T4 in the present study.
This is likely because most of the circulating THs in
plasma are bound to TH binding proteins [2], and after
complete deproteinization of serum samples, THs were

















































































































































































































































































































































































Sphingosine 1-phosphate PalmitateC18 Sphinganine 1-phosphate
C22-OH Sulfatide C24-OH Sulfatide C24:1-OH Sulfatide
Figure 11 Boxplots of metabolites in the sphingolipid metabolism pathway. “d”, 1,3-dihydroxy long-chain base.
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Figure 12 Significant abundance changes of the metabolites in the eicosanoid metabolism pathway. The superscripts indicate that the
metabolites have the same mass and cannot be differentiated. (A) Overall abundance changes of the metabolites. (B) Progression of the
abundance change of the metabolites relative to the premetamorphic stage (TK VI–X). Refer to Figure 4 legend for details. Metabolites with the
same superscript letter (a, b, or c) share the same mass and cannot be distinguished from each other.
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system and acts on both transient receptor potential
vanilloid type 1 (TRPV1) and cannabinoid type 1 (CB1)
receptor. The novel properties of NADA as an antioxidant
and neuroprotectant have been discovered [77], and
NADA has been shown to induce TRPV1-dependent cell
death in neurone-like cells independent of caspase activity
[78]. Studies indicate that the CB1 receptor is implicated
in brain and neuronal development [79]. Taken together,
this may indicate that NADA may affect brain and neur-
onal development during metamorphosis.
Other metabolites
Outside the aforementioned metabolic pathways, we de-
tected cis-aconitate, histidine, and riboflavin (Figure 6).
The abundance pattern of cis-aconitate increased around
TK XVIII followed by a gradual decrease until the froglet
stage, possibly representing the metabolic status of the
citric acid cycle as cis-aconitate is an intermediate in the
conversion of citrate to isocitrate. Riboflavin exhibited a
peculiar abundance change, increasing until TK XVI–
XVII followed by a decrease at stage XVIII then increas-
ing again until TK XXI–XXII, finally plummeting at the
froglet stage (Figure 6). Riboflavin is a versatile metabolite
and is the core component of flavoproteins. Flavoproteins
have various roles in redox reactions, signal transduction,programmed cell death, regulation of biological clocks,
and light-dependent repair of DNA damage [80]. The re-
quirement for the versatile actions of flavoproteins likely
increases during metamorphic remodelling.
Conclusions
Using a validated metabolomics approach, we were able to
identify key metabolites and metabolic pathways - arginine
and purine/pyrimidine, cysteine/methionine, sphingolipid,
and eicosanoid metabolism and the urea cycle - that are
significantly remodelled during bullfrog metamorphosis. Of
particular note is the prominent role of lipids providing a
new mechanistic avenue in the control of this important
postembryonic developmental process. Since metamor-
phosis is hormonally-controlled, the discoveries herein
draw attention to systems that present as strong candidates
for TH-mediated coordination of organism remodelling.
Methods
Animals and serum collection
R. catesbeiana tadpoles used in the present study were
caught locally and were maintained in accordance with
the guidelines of the Canadian Council on Animal
Care and the University of Victoria (Permit # 2010-030).
Euthanasia was performed using buffered tricaine metha-
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Figure 13 Boxplots of metabolites in the eicosanoid metabolism pathway.
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http://www.biomedcentral.com/1471-213X/14/5Canada) at either 0.1% (w/v) for tadpoles or 1% (w/v) for
froglets. The solutions contained 25 mM of sodium bicar-
bonate and were freshly prepared in dechlorinated tapwater immediately before use. Animals were individually
staged according to TK staging [12]. To obtain blood, a
deep, vertical incision was made on the tail musculature
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collected using a pipettor and transferred to a microcentri-
fuge tube. The blood was allowed to coagulate for 15 min
at room temperature and then centrifuged at 4°C at
16,000 × g for 10 min. The serum was separated from
the cell pellet, flash frozen in liquid nitrogen and stored
at -80°C until further processing.
Seven different TK stage ranges were used in the
present study: VI–X, XII–XV, XVI–XVII, XVIII, XIX–
XX, XXI–XXII, and > XXV. For each TK stage range, 12
biological replicates were obtained, hence there were 84
samples in total. Because the volumes of three of the
serum samples obtained from metamorphs at TK XXI–
XXII were insufficient, these samples were not tested,
and the number of biological replicates for stage TK
XXI–XXII was 9. Therefore, a total of 81 serum samples
were analyzed in the present study.
“Total” metabolite extraction
To reduce the possibility of systematic error, the samples
were processed in a randomized order. Twenty-five μL
of serum from each tadpole were mixed with 25 μL of
water in a 0.65 mL-microcentrifuge tube, and 500 μL of
acetonitrile was added. The tube was vortexed vigorously
and then placed on ice for 30 min to completely precipi-
tate proteins. Following centrifugation at 4°C at 12,000 × g
for 10 min, 500 μL of the supernatant were transferred
to a V-tapered sample vial and then dried in a Savant
SPD1010 SpeedVac concentrator (Thermo Electron,
Milford, MA, USA). The residues were reconstituted in
40 μL of 20% isopropanol, of which 7.5 μL were injected
for each UPLC-mass spectrometry (UPLC-MS) run.
Liquid-liquid extraction of polar (aqueous) metabolites
Fifty μL of each tadpole serum sample were mixed with
500 μL of methanol in a 1.5-mL Eppendorf tube. After
15 s × 2 vortex-mixing, the tube was placed on ice for
30 min and centrifuged as above. Following centrifuga-
tion, 500 μL of the supernatant were transferred to a
1.5-mL Eppendorf tube and mixed with 175 μL of water
and 350 μL of chloroform. Following a brief vortexing,
the tube was centrifuged at 4°C at 12,000 × g for 10 min
to separate the whole phase into aqueous (upper) and
organic (lower) phases. Five hundred μL of the aqueous
phase were carefully transferred to a V-tapered sample
vial and dried in the same SpeedVac concentrator. The
residue was reconstituted in 50 μL of 90% acetonitrile
and 5 μL were injected for UPLC-MS.
UPLC-MS
All data files were acquired on an Acquity UPLC system
coupled to a Synapt Q-TOF mass spectrometer (Waters,
Milford, MA, USA). UPLC-MS was performed using two
columns: a Waters BEH C18 (2.1 mm I.D. × 100 mm,1.7 μm) column for the total metabolite extracts and a
Waters BEH Amide (2.1 mm I.D. × 100 mm, 1.7 μm)
column for the separation of very polar metabolites. On
the C18 column, a binary solvent gradient elution was
used to chromatograph the metabolites with 0.01% formic
acid in water as mobile phase solvent A and isopropanol-
acetonitrile (1:1, v/v) containing 0.01% formic acid as
mobile phase solvent B. Column temperature was kept
at 45°C, and the flow rate was 0.25 mL/min. The binary
gradient was from 8% to 40% solvent B in 5 min, 40% to
100% solvent B in 17 min, and then 100% solvent B for
3 min. The column was re-equilibrated with 8% solvent
B for 5 min before the next injection. With the Waters
Amide column, a binary solvent gradient elution was
used to separate the metabolites with acetonitrile con-
taining 0.01% formic acid as solvent A of the mobile
phase and 0.01% formic acid in water as solvent B of the
mobile phase. Column temperature was 30°C, and the
flow rate was 0.25 mL/min. The binary gradient was
10% to 70% solvent B in 12 min, 70% solvent B for
2 min and then the column was reconditioned with 10%
solvent B for 6 min before the next injection.
The eluted metabolites were ionized by electrospray
ionization (ESI) and detected in both the positive and
negative ion modes over the mass range m/z 100-1000.
This resulted in 4 UPLC-MS datasets per sample (i.e., 4
UPLC-MS runs per sample were carried out): total extract
ESI(+)(Tot+), total extract ESI(–)(Tot-), aqueous extract
ESI(+)(Aqu+), and aqueous extract ESI(–)(Aqu-). The typ-
ical ESI-MS parameters included an ESI spray voltage of
3-3.2 kV, desolvation gas (N2) flow of 750-800 L/h, a
temperature of 350°C, drying gas (N2) flow of 50 L/h and
temperature of 130°C, sampling cone voltage of 35 V,
extraction cone voltage of 4 V, and data acquisition rate
of 0.25 s. The background argon gas in the collision cell
was kept at 0.8 mL/min. A lock-mass spray (50 pg/μL
leucine enkephaline in 60% isopropanol at 5 μL/min)
was employed to ensure the mass accuracy of the TOF
throughout the UPLC-MS runs.
Data preprocessing
Raw UPLC-MS data were converted to the netCDF files
using the Waters Databridge translation utility. The result-
ing data files from each dataset were then processed using
the XCMS package [81], an R package which performs
non-linear correction of retention time (RT) shifts. Peak
detection and integration was performed using the cen-
tWave algorithm [82]. RT shift correction was achieved
considering at least 200 peak groups. After two itera-
tions of peak grouping, peak filling was done using the
“fillPeaks” routine of the XCMS package. Finally, a data
matrix was generated from each UPLC-MS dataset and
exported into Microsoft Excel. After removal of the signifi-
cant background noise signals observed in each UPLC-MS
Ichu et al. BMC Developmental Biology 2014, 14:5 Page 20 of 23
http://www.biomedcentral.com/1471-213X/14/5blank run and manual de-isotoping, the individual data
matrices were saved as two-dimensional (m/z-RT pair vs.
peak area) data tables amenable to subsequent statistical
analyses.
Statistical analysis
All statistical analyses were performed using the R pro-
gramming language [83]. The data analysis work flow is
presented in Figure 14. The peak area values in the data-
sets were log2 transformed to reduce variance and to
make the skewed distributions of the data more symmet-
ric. One sample from the Tot- set produced poor signal
for most metabolites and was removed from the analysis.
Box plots were made for all metabolites, and the abun-
dance pattern of each graph was inspected thoroughly.
The patterns of the graphs were classified into one of
thirteen categories that consistently appeared (Table 3).
To identify metabolites with differential abundance pat-
terns at different TK stages, the Kruskal-Wallis test was
performed for each metabolite under the null hypothesis
of the same median log2 peak integration values across
all the TK stages. The Kruskal-Wallis test assumes that
the distributions of data for each metabolite at different
TK stages have identical shapes, implying that these distri-
butions have equivalent variances. Violation of this con-
stant variance assumption results in inaccurate p-values,
hence unreliable results. To prevent this, each metabolite
was tested for equal variance using Levene’s test using a
median as the central location parameter of a distribution.
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Figure 14 Data analysis work flow. After preprocessing of the
data, it was analyzed with the indicated decision points.multiple comparisons by controlling the FDR as proposed
by Benjamini and Hochberg [84]. After the adjustment,
metabolites with padj <0.01 were determined to have sig-
nificantly different variances, and these metabolites were
separated prior to the Kruskal-Wallis test. After perform-
ing the Kruskal-Wallis test, the p-values were adjusted by
controlling the FDR using the method by Benjamini and
Hochberg [84], and metabolites showing highly statisti-
cally significant abundance changes (padj <0.001) were
chosen for further database search. PCA was performed to
display the relationship between TK staging and the abun-
dance profiles of significant metabolites. For a data matrix,
n × p where n = samples (tadpoles) and p = significant
metabolites, PCA was performed by centering the data
matrix by column-wise medians and then singular value
decomposition of the median-centered data matrix.
Scaling was not performed because of the wide range of
metabolic abundance changes.
Database search, identification of metabolites and
pathway construction
The metabolite features whose abundance profiles
showed significant heteroscedacity at a certain TK stage
or significant abundance changes were searched against
the MassTRIX ver. 3 webserver [85] (http://masstrix3.
helmholtz-muenchen.de/masstrix3/). For the ESI+ gen-
erated datasets (Tot+ and Aqu+), [M+H]+ and [M+Na]+
were selected as possible adducts while [M-H]- was
chosen as a possibility for the ESI- generated data (Tot-
and Aqu-). The allowable mass error was set to 0.02 Da,
and KEGG/HMDB/LIPID MAPS [86-88] without isotopes
was selected as the database. Because Rana catesbeiana
was not available as a choice of organism, Homo sapiens
was chosen due to the completeness of the database and
the similarities in genetic diversity and metabolomic sys-
tems. In the optional pathway analysis field, 90 different
KEGG pathway IDs were pasted in order to obtain a com-
prehensive coverage of the possible locations of the me-
tabolites in metabolic pathways. These pathways included
the citric acid cycle, fatty acid synthesis, steroid hormone
biosynthesis, amino acid metabolism and degradation, etc.
When there were multiple hits for the possible IDs of one
metabolite, the most likely ID was inferred based on the
chemical profile of the metabolite (retention time, ESI
mode, existence of similar metabolites, etc.). We focused
only on those masses with only one possible ID or where
all but one ID had been eliminated by chemical profile
evaluation. Using the KEGG pathway maps in which the
locations of query metabolites were highlighted, we con-
nected and constructed metabolic pathway maps. For each
metabolite, the integration values at the indicated TK
stage ranges were compared to the values at the preme-
tamorphic stage as a control, using the nonparametric
multiple comparison procedure for unbalanced one-way
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were FDR-corrected, and a significance level of 0.05 was
used.
Validation of selected metabolites
Authentic compounds for the selected metabolites were
obtained as shown in Table 2. These compounds were
prepared and diluted to a final concentration of 10 μg/mL
in 20% isopropanol for the metabolites observed in total
extracts and 90% acetonitrile for the metabolites observed
in aqueous extract. The standards were run and analyzed
under the same conditions as described in the UPLC-MS
section.
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